Protein self-assembly is critical for numerous biological processes. Yet, assembly is rarely targeted by therapeutic agents, in part because it is hard to identify molecules that interfere with protein-protein interactions. Here, we describe a simple fluorescencebased screen for self-association and its application to the assembly of hepatitis B virus capsids. These data are analyzed to identify kinetic and thermodynamic effects-both of which are critical for the viral lifecycle and for understanding the mechanism of assembly effectors. Suggestions are made for modification of this protocol so that it can be applied to other self-assembling systems. With manual pipetting, setting up a plate takes about 2 h, the initial reading takes 1 h and the end point reading the following day takes about 5 min.
INTRODUCTION
One can still hear the opinion that protein-protein interactions are not viable targets for small molecules. Yet, effectors of cytoskeleton self-assembly are commonly discussed in cell biology text books 1 : microtubules are stabilized by paclitaxel and destabilized by colchicine; actin filaments are stabilized by phalloidin and destabilized by cytochalasin B. These small molecule effectors show tight binding and are specific. They are powerful tools for ''chemical genetics'' where the lesions they induce give new insights into cell biology 2 . Although there are therapeutic uses for most of the molecules mentioned, they are extremely toxic because they target cytoskeletal proteins common to every cell.
Viruses are an example of biological self-assembly where the reaction is distinct from any process in a healthy host cell. For spherical viruses, there is a protein shell, or capsid, constructed from hundreds of copies of the capsid protein(s). In this way, viruses use a minimal amount of their genome to envelope the maximum volume by prodigal use of their host's resources. Generally, capsid proteins are not homologous to any known host proteins. Most antiviral therapeutics target viral enzymes such as proteases or polymerases. We suggest that virus self-assembly should be an ideal target for a new generation of antivirals [3] [4] [5] ; although not commercialized, virus-stabilizing molecules have already been tested as potential antiviral agents [6] [7] [8] . Similarly, heteroaryldihydropyrimidines (HAPs), which attenuate hepatitis B virus (HBV) production in tissue culture 9 work by affecting capsid assembly and structure [10] [11] [12] [13] [14] . However, these antivirals were not found when searching for assembly effectors.
This protocol describes an assay for identifying small molecules that directly affect capsid stability and assembly 15 . HBV is an ideal test bed for these studies because assembly is critical to the virus lifecycle and there is a reliable, well-characterized in vitro assembly system. HBV is a DNA virus with an RNA pre-genome that is reverse transcribed within newly assembled capsids 16 . The capsid protein is a homodimer 17 that spontaneously self-assembles into a mixture of 120-dimer (T¼4) and 90-dimer (T¼3) icosahedral particles when expressed in Escherichia coli 18 . Both sizes are seen in vivo 19 , as well as in E. coli 3 , although the larger size predominates in both. Image reconstructions 20 and X-ray structures 13, 21 of expressed capsids are indistinguishable from the structure of the core in enveloped, infectious virions 22 . Purified E. coli-expressed core protein dimers, lacking the RNA-binding domain, spontaneously reassemble in vitro as a function of protein concentration, temperature and ionic strength 23, 24 . To facilitate unique labeling at the C terminus of the HBV capsid protein, we engineered a mutant capsid protein, C150, in which the native cysteines are mutated to alanine and a C-terminal cysteine was included. When that cysteine is modified with the fluorescent dye BoDIPY-FL, we refer to the construct as C150Bo. C-termini are at the extreme ends of free dimer. In capsids, the C-termini cluster together allowing the BoDIPY molecules to form a dimer that is essentially nonfluorescent ( Fig. 1) (see ref. 15 ). We have shown that changes in fluorescence correlate with HBV capsid protein assembly to yield either capsid or, when assembly is misdirected by a HAP, large hexagonal complexes 15 .
The last piece of background information needed to interpret assembly data is an understanding of the current thinking on mechanisms of capsid assembly. Experimentally, capsids do not assemble below a threshold concentration; above the threshold concentration, assembly has sigmoidal kinetics, marked by the transient appearance of low concentrations of intermediates. The simplest case model of assembly describes the reaction as a cascade of fast, low-order reactions that follow a rate-limiting nucleation step that can readily be written as a master equation (i.e., a balanced system of rate equations) 3, 25 . Such models give rise to sigmoidal kinetics because capsids cannot appear until a complete ladder of intermediates is sequentially synthesized 23 . At equilibrium, assembly of N protomers (the mono-or oligomeric fundamental unit of assembly) is expected to follow the law of mass action 3 :
Because of the extreme power dependence, there is negligible assembly when the concentration of free protomer is low, whereas above a threshold, or pseudo-critical concentration, almost all the protein present in solution aggregates to form capsids. This behavior is observed for HBV 24 and most viruses examined [26] [27] [28] [29] . Other methods for analytically modeling assembly such as molecular dynamics 30, 31 and discreet event simulators 32 recapitulate the behavior predicted from master equation approaches. Because the rate of assembly does not necessarily reflect the extent of assembly, both sorts of information are necessary for evaluating assembly and assembly effectors; see 'Anticipated Results' .
Expanding the protocol to other virus/protein systems The present protocol was developed for a mutant HBV core protein in which the native cysteines were mutated to alanine and a C-terminal cysteine was appended. Because this assay is applicable to any virus, or protein, for which there is an in vitro assembly assay, it is useful to provide generalization for adapting it to other systems. For almost every virus, assembly juxtaposes the N-or C termini of the capsid proteins (see the VIPER database for examples 33 ), making these ends particularly suitable for labeling. It is not necessary to mutate native cysteines if they are not accessible to free dyes. Accessibility of native cysteines can be tested using Ellman's reagent 34 (see Box 1) . An N-or C-terminal cysteine can be incorporated using standard molecular biological techniques. As an alternative to cysteine, the N-terminal amine of a protein (if it is not modified) has a pK of about 7 and in some cases can be specifically labeled using succinimide chemistry.
In other systems, it may be necessary to consider other fluorophores. BoDIPY-FL quenching is dominated by formation of a ground-state dimer; therefore, it is most useful when assembly places labels in contact with one another. Otherwise, BoDIPY-FL fluorescence is almost insensitive to environment 35 . At that point, it becomes necessary to consider alternative assays such as using BoDIPY-FL anisotropy or other dyes, labeling sites and detection strategies. For example, the target protein can also be modified with FRET (fluorescence resonance energy transfer) pairs 36 , although the assay will be dependent on the juxtaposition of distinctly different dyes instead of a single dye. Common FRET pairs include fluorescein and rhodamine. Unlike the BoDIPY dyes, the absorbance and fluorescence of most fluorophores are exquisitely sensitive to environment, and this effect must be considered when observing FRET or anisotropy. If adapting this protocol to a different protein, it should be kept in mind that maleimides will react with nucleophilic (unprotonated) amines and will preferentially react with the unprotonated form of cysteine. Thus, when appending a fluorescent probe, it is best to maintain the pH of the protein solution between 6.5 and 7.5 using a buffer that does not contain primary amines.
Deciding on assembly thresholds and assay type
The goal of this screen is to examine the effect of small molecules on assembly. The basic strategy is to preincubate capsid protein with a small molecule and then induce assembly. In the case of HBV, assembly is induced by raising ionic strength. It is straightforward to determine the extent of assembly under a range of protein concentrations and ionic strengths. It is critical to decide how much assembly is needed to obtain interpretable results (see also PROCEDURE). For assembly inhibitors, it is desirable to have 50% assembly. For assembly enhancers, we choose 25-30% assembly, on the basis of a standard curve of fluorescence as a function of protein concentration (see Step 8 of PROCEDURE). 
BOX 1 | TEST FOR FREE CYSTEINES USING ELLMAN'S REAGENT
(1) Make a 20 mM stock of Ellman's reagent (dithionitrobenzoic acid) by dissolving 12 mg in a minimum volume of acetone and then adding deionized water to a final volume of 1.5 ml (2) Transfer the protein to a slightly basic buffer, such as 50 mM sodium borate pH 8.5. To accomplish this buffer exchange, use a desalting column such as PD10 or equivalent Sephadex G25 column, and follow the directions in Step 2 of PROCEDURE m CRITICAL STEP For this assay, it is necessary to remove any reducing agent (i.e., DTT) from the protein solution (3) Determine the protein stock concentration by absorbance. It is advisable to have at least 10 mM protein for this assay. Your protein's extinction coefficient at 280 nm can be estimated by scoring 5,500 M À1 cm À1 for each tryptophan, 1,490 M À1 cm À1 for each tyrosine and 125 M À1 cm À1 for each disulfide 39 (see also http://www.expasy.com). To minimize use of protein in this and the next step, use black masked 100 ml microcuvettes with a 1 cm optical path length (4) Mix 100 ml of buffer (as a control) or protein solution with 20 ml of Ellman's reagent stock solution. After 20 min, read the absorbance at 412 nm. Ellman's reagent modifies free cysteine and releases one thionitrobenzoate, which has an extinction coefficient at 412 nm of 13,600 M À1 cm À1 . Keeping in mind the 5/6 dilution (and assuming a 1 cm cuvette), the concentration of solvent-exposed thiol in the protein sample is ½thiol ¼ 6=5ðA 412;protein À A 412;blank Þ=13; 600 M À1 cm
À1
This should be compared to the protein concentration to determine the number of solvent-accessible cysteines per protein
The simplest assay is an end-point analysis, the extent of assembly at equilibrium (24 h for HBV). However, because in vivo assembly is sensitive to changes in kinetics and thermodynamics, there is a great deal of information to be obtained by observing the kinetics of assembly (Fig. 2) . Changing the rate of a reaction does not always affect the reaction extent, and vice versa (Fig. 3) . When there are 96 or more samples, it is impractical to induce one reaction at a time. To observe kinetics at coarsely sampled time points, conditions must be chosen so that the half time of assembly is later than the first time points, on the order of 10 min, which is conveniently consistent with 25-30% assembly.
Choice of kinetic model
No simple model adequately describes a reaction as complex as virus assembly. The reaction is nominally second order as subunits 37 and small complexes of subunits 32 add to a growing capsid. The result is that kinetics are nominally sigmoidal and slowly, asymptotically approach equilibrium 25 . For screening purposes, because we are more interested in developing indices of assembly, we propose a curve fit with an oversimplified model. We suggest a hyperbolic model as a first approximation (Fig. 2) . The hyperbolic curve we have chosen fits fluorescence over time and is expressed as follows:
where F init is the initial fluorescence of unassembled protein, determined from the ''no-assembly'' controls (see PROCEDURE). F final is a fit parameter; a good starting estimate is the fluorescence at 24 h (1,440 min). The reciprocal of the time constant, k t , is the time it takes the reaction to achieve 50% of its dynamic range. The exponential term, n, is optional. It can be included to accommodate the fact that assembly kinetics are not hyperbolic; an exponential term allows fitting to kinetics that are sigmoidal and have either a very long lag phase or are fast and then level off. In some respects, it is analogous to a Hill coefficient 38 
PROCEDURE Protein labeling TIMING 2 days
1| Make a 50 mM stock of maleimidyl BoDIPY-FL dye by dissolving 5 mg of maleimidyl BoDIPY-FL in 241 ml of dry DMSO. ' PAUSE POINT Stocks may be stored at À80 1C for at least 2 months.
2| Remove DTT from the protein stock (typically 45 mM Cp149 in storage buffer; see Box 2) by desalting a 0.5 or 1 ml aliquot on a PD10 or equivalent Sephadex G25 column equilibrated with ice-cold 50 mM HEPES pH 7.5. Collect 0.5 ml fractions and pool fractions (usually 2-3 fractions in the pool) based on absorbance at 280 nm. The protein is typically diluted by 1/3. Determine the protein concentration by absorbance at 280 nm (e¼ 60,900 M À1 cm À1 ), a standard extinction coefficient for the HBV assembly domain 23 . We use a black masked 100 ml microcuvette with a 1 cm optical path length. m CRITICAL STEP All column chromatography should be performed at 4 1C. We have found that room temperature chromatography of free HBV dimer can lead to a loss of assembly activity. 3| In a 1.5 ml microcentrifuge tube, mix 0.98 ml of protein with 20 ml of stock maleimidyl BoDIPY-FL so that there is at least a 20-fold molar excess of dye. Cover the tube with aluminum foil to protect it from light. ' PAUSE POINT Incubate the solution overnight at 41C.
4| Remove DMSO and unreacted dye from the solution using a PD10 or equivalent column equilibrated with ice-cold 50 mM HEPES pH 7.5. Collect 0.5 ml fractions and pool fractions on the basis of absorbance of the BoDIPY at 504 nm. Labeled protein will appear in the void volume of this mini-column and is obvious to the naked eye (Fig. 1) . Many dyes, including BoDIPY-FL, bind size-exclusion gels presumably by hydrophobic interactions. As these dyes cannot be efficiently washed off the column, discard the packing (or the entire column) after each use. The modified protein is referred to as C150Bo. 
BOX 2 | PURIFICATION OF HEPATITIS B VIRUS CORE PROTEIN ASSEMBLY DOMAIN (C150)
This box is primarily included for informational purposes. The protocol assumes that you have frozen cell paste of an E. coli clone that overexpresses HBV capsid protein assembly domain. The purification protocol is based on published protocols. 3, 42 We use BL21-DE3 carrying a pET11 plasmid with the assembly domain expression under control of a T7 promoter (the cells and plasmid are from Novagen; the Cp149 insert is the generous gift of PT Wingfield). The Cp149 was mutated to C150 using a QuikChange Multi Site-Directed mutagenesis kit (Stratagene) to replace cysteines at positions 48, 61 and 107 with alanines and to add a C-terminal cysteine; details of the mutagenesis are described in Stray et al. 15 .
(1) Resuspend E. coli cell paste (1 g paste per 4 ml buffer) with 50 mM Tris pH 7.5, 5 mM DTT, one protease inhibitor cocktail tablet per 10 ml (Roche), 0.01 mg ml À1 DNase, 0. Load the supernatant onto a buffer A-equilibrated Sepharose CL-4B column (B350 ml bed volume in a 2.6-cm-diameter column, maximum load volume is 5% of bed volume or 17 ml) at 4 1C. Run the column at a flow rate of 1 ml min À1 . Collect forty 7-ml fractions after having discarded the first 100 ml of flow-through ' PAUSE POINT Column can be run overnight. m CRITICAL STEP All columns should be stored and run at 4 1C to preserve protein integrity. Load capsid sample on a buffer N-equilibrated 1 liter Sephacryl S-300 XK-50 (maximum load volume 50 ml) or 350 ml S-300 column (maximum load volume 17 ml) at 4 1C. Elute at B4 ml min À1 (1 liter column) or B1 ml min À1 (350 ml) collecting 16 or 7 ml fractions, respectively ' PAUSE POINT Column can be run overnight. 5| To quantify the efficiency of labeling, measure the absorbance at 280 and 504 nm, A 280 and A 504 (Fig. 4) 7| Generate an assembly standard curve at 150 and 300 mM NaCl to determine the pseudocritical concentration of free dimer; above this concentration, nearly all additional protein goes to form capsid (see also ANTICIPATED RESULTS). In a pretreated plate, set up two columns in the plate with 40 ml samples of C150Bo, where each column has wells at concentrations of 0, 1, 2, 3, 4, 5, 6 and 7 mM prepared by diluting C150Bo stock with 50 mM HEPES buffer pH 7.5. m CRITICAL STEP Because there is some batch-to-batch variation in C150Bo, the K D apparent for capsid formation should be determined empirically. Generally, the K D apparent for C150Bo at 150 mM NaCl is about 4 mM; at 300 mM NaCl, the K D apparent is approximately 1 mM.
8| Initiate assembly by adding to each sample 10 ml of 750 mM NaCl in 50 mM HEPES buffer pH 7.5 to one column of wells and 10 ml of 1,500 mM NaCl in 50 mM HEPES buffer pH 7.5 to the other column. Mix reactions by aspiration.
9| Prepare control solutions as follows: for full-assembly control, mix 25 ml of 10 mM C150Bo with 25 ml of 2 M NaCl in 50 mM HEPES pH 7.5. For no-assembly controls, mix 25 ml of 10 mM C150Bo with 25 ml of 50 mM HEPES pH 7.5. Also prepare buffer blanks. Cover the plate with sealing tape. ' PAUSE POINT Allow the reaction to equilibrate for 24 h. the excitation wavelength to 485 nm and the emission wavelength to 512 nm.
11|
The fluorescence of the full-assembly control should be no more than 1/10 the fluorescence of the no-assembly control. After background subtraction (signal from wells containing buffer only), the fluorescence data should be normalized to percent assembly:
% assembly sample ¼ 100 F sample À F fullÀassembly F noÀassembly À F fullÀassembly m CRITICAL STEP For calibration, include triplicate controls of full-assembly, no-assembly and buffer (as a blank). For screens, (below) include triplicate controls of full-assembly, no-assembly, 25% assembly and buffer background. It is better to repeat experiments with assembly effectors in triplicate on 3 different days to ensure that assays are independent, rather than to test each compound in triplicate on the same plate.
Assay assembly effectors TIMING 2 h on day 1 and 10 min on day 2 12| We choose protein concentrations where we have 25-30% assembly as the best compromise for identifying enhancers and inhibitors and allowing us to observe HBV assembly kinetics. For a typical C150Bo stock, 25% assembly is achieved at 5.25 mM dimer. Prepare a stock solution of 1.25Â the concentration of C150Bo (6.6 mM for this typical case). For each compound to be tested and each control, add 37.5 ml of stock protein solution to a well.
13|
To each well, add 10-20 mM of a compound to be tested and incubate for 30 min. For screening purposes, the compound should be in molar excess of the capsid protein. As compound stocks are typically 20 mM in DMSO, an aliquot of this stock is diluted 1:99 with 50 mM HEPES to 0.2 mM. Dilution into buffer decreases the amount DMSO added to the reaction. A 2.5 ml portion of diluted compound or buffer + DMSO (as a control) is added to each well. Add 2.5 ml of 1% (v/v) DMSO to each control sample. Total volume is now 40 ml. m CRITICAL STEP This assay depends on keeping all reactants in solution. If a well appears cloudy due to precipitation of compound and/or protein, the results from that sample are not valid. m CRITICAL STEP DMSO in high concentrations does affect assembly. C150Bo assembly is not affected by p1% DMSO. If you are studying assembly of other proteins or using other solvents, be sure to control for solvent effect.
14| To obtain a final concentration of 150 mM NaCl in 50 mM HEPES pH 7.5, add 10 ml of 750 mM NaCl and mix by aspirating. For controls, add 10 ml buffer with no NaCl (0% assembly), buffer with 5 M NaCl (100% assembly) and buffer with 750 mM NaCl (25% assembly).
15| Take readings (as described in Step 10). For kinetic studies, read fluorescence at 5-min intervals after mixing; continue readings for 1 h, then cover the plate and store in the dark at 21 1C. ' PAUSE POINT For the final point in the kinetic experiment and for end-point analysis, read fluorescence after 24 h. ? TROUBLESHOOTING 16| Convert fluorescence to % assembly (see Step 12) . If you are not interested in observing kinetic effects on assembly, this protocol ends here. Otherwise, consult the Data analysis section and ANTICIPATED RESULTS. ? TROUBLESHOOTING Data analysis 17| For fitting raw fluorescence data (see Choice of kinetic model in INTRODUCTION), hold F initial constant, as it is experimentally determined. Allow F final to vary; however, to prevent absurd curve fits, limit its value to less than or equal to the average of the fluorescence at 60 and 1,440 min. In cases where assembly is very fast, curve-fitting routines will settle on unrealistically fast time constants; when assembly is altogether prevented, time constants will often be unrealistically slow and may have extremely high or even negative values for F final . For a %assembly fit, % final is adjustable and should have the same characteristics as F final , that is, a starting value of %assembly at 1,440 min and a minimum value of the mean of assembly at 60 and 1,440 min. The time constant, k t , must be allowed to float freely; a useful starting value is 20 min. Cooperativity, n, can be held at 1.0 or allowed to freely float. For HBV, where the lag phase is not particularly extreme, we hold n ¼ 1.
18|
To fit assembly, we routinely use the ''solver'' add-in for Microsoft EXCEL or Kaleidagraph. For describing the data, including the curve fits, useful terms are 1/k t , calculated final assembly based on F final or %assembly, cooperativity (n) and the experimentally observed assembly at 24 h.
19|
Using the %assembly data, the effect of a small molecule on the assembly association constant can be evaluated (see ref. 24) Step Problem Solution 5
Nonspecific, non-covalently associated dye can persist after initial purification and will interfere with assembly screens by affecting the protein, increasing the background and decreasing the dynamic range of the assay. It is usually seen as more than two dyes per C150 dimer or, after 24 h, the C150Bo sample becomes slightly cloudy and reddish due to aggregation of the free dye Colored small molecules Small molecules that absorb light in the same range as excitation and emission will decrease the fluorescence output due to an ''inner filter'' effect 41 . The inner filter effect can be corrected for the absorbance of the small molecule:
where F observed is the observed fluorescence. The absorbance can be calculated from the extinction coefficient, concentration, and path length using Beer's law. We determined that the path length was 0.2 cm for 50 ml samples in a 96-well format; this was accomplished by generating a standard curve of free BoDIPY emission in the presence of different non-fluorescent molecules of known concentration and extinction coefficient. The inner filter effect is negligible for molecules with an extinction coefficient o25,000 M À1 cm À1
ANTICIPATED RESULTS Quantifying labeling (Step 5)
A protein absorbance spectrum is dominated by tryptophan and tyrosine, resulting in a broad peak at 280 nm with a shoulder at 295 nm 41 . There is some BoDIPY absorbance in this region, but, for C150Bo, at 504 nm only BoDIPY absorbs light. For the sample shown in Figure 4 , the reading at 504 nm is 1.05. As shown in Step 5, using an extinction coefficient of 78,000 M À1 cm À1 , the concentration of BoDIPY-FL in the sample is 14.8 mM. The concentration of protein in the sample is determined from the absorbance at 280 nm, 0.485, using an e280 C150 ¼ 60,900 M À1 cm À1 , less the absorbance due to BoDIPY (e280 ¼ 1300 M À1 cm À1 ). This results in a protein concentration of 7.8 mM. The ratio of BoDIPY to protein concentration is the number of dyes per dimer, in this case 1.9.
Calibrating assembly (Steps 6-11) The goal of calibrating assembly is to determine a concentration of C150Bo that will be most sensitive to assembly effectors under given assembly conditions. For this purpose, we have selected the best scenario to be one in which 25% of the total protein assembles and 75% remains as a free dimer. Given that at 150 mM NaCl, the pseudo-critical concentration of assembly is 4 mM, then at a concentration of 5.25 mM C150Bo, 1.25 mM C150Bo will be assembled and 4 mM will be in the dimer form.
(The pseudo-critical concentration is approximately equal to K D apparent , the point where there are equimolar concentrations of free dimer and capsid. K D apparent in turn can be directly related to the pairwise association constant, K contact 3-5 .) After subtracting the background for all samples, the fluorescence of free and assembled protein can be estimated from the control samples for all protein concentrations. The amount of assembly for each sample can then be calculated for each test sample using the equation in Step 11 and the control values for ''no-assembly'' and ''full-assembly.''
Results from a screen (Steps 12-16) The change in assembly over the course of 1 h for five samples is shown as solid lines in Figure 2 . Three standard samples are (a) no additives (25% assembly), (b) +3.6 mM HAP1 and (c) +0.7 M urea. It is clear that most assembly occurs in the first few minutes for the first two samples and that urea practically halts assembly. Compound B37 has no detectable effect on assembly. Compound B36 markedly enhances assembly. Second-order curve fits (Fig. 3, dashed lines) , shown for B36 and B37, clearly are an approximation with systematic deviation. Nonetheless, the reciprocal of the time constant is a useful approximation for describing assembly kinetics.
These data are summarized in Figure 3 . For 25% assembly of 5.25 mM C150Bo, induced by 150 mM NaCl, the DG contact is À3.38 kcal mol À1 (calculated as in Step 19) . The presence of 3.6 mM HAP1 + 150 mM NaCl results in 65% assembly, indicating an association energy of À3.65 kcal mol À1 . Although this change (HAP1 enhances assembly by DDG ¼ À0.27 kcal mol À1 ) is relatively small per contact, it must be understood that there are 240 such contacts per capsid. The noise inherent in this system (i.e., the standard deviation) is about ±5 percentage points. The reciprocal time constant generally tracks with the %assembly, about 10 min for the 25% assembly control and 2 min for the HAP1 + 150 mM NaCl. In some cases (e.g., B45), assembly speeds up even though the increase in assembly is not all that great. Misdirected assembly, assembly of non-capsid polymers, is a very desirable outcome for an assembly effector. There is no direct readout for misdirection from this high throughput assay. However, we can make the generalization that misdirected assembly proceeds without ''editing'' to remove incorrectly incorporated subunits. This lack of editing is predicted to be more likely when assembly is much faster or much stronger 25 ; faster and/or stronger can be detected using this assay
Final comments
The protocol described in this paper will allow one to observe assembly in vitro and screen small molecules that affect assembly. The analyses described in this protocol are intentionally crude-they allow the experimentalist to identify which molecules affect assembly and which do not, but they tell little about the mechanism of binding. All experiments here are at relatively high concentrations of effector, 10 mM; we are looking for an effect, not a dissociation constant. Fundamentally different experiments will be required to identify the significant mechanistic details: K D , effects on nucleation and elongation rate constants and morphology of assembly products. The simple curve fits developed here are an index for activity and should not be interpreted otherwise. The true kinetic trajectories are generally sigmoidal but can adopt much more complex shapes in response to changes in reaction conditions 12, 42 
